Kaposi sarcoma associated with rituximab-based cytotoxic therapy
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.26, sa.1, ss.220-223, 2020 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 26 Sayı: 1
- Basım Tarihi: 2020
- Doi Numarası: 10.1177/1078155219835592
- Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
- Sayfa Sayıları: ss.220-223
- Anahtar Kelimeler: Rituximab, Kaposi sarcoma, lymphoma, HHV-8
- İnönü Üniversitesi Adresli: Evet
Özet
Kaposi sarcoma (KS) is a low-grade mesenchymal angioproliferative disease, mostly observed in immune compromised patients. KS is mostly encountered in HIV-positive or organ transplant patients. The drugs causing immunosuppression have also been associated with KS. Here, we present a KS experience associated with rituximab-based therapy.